Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
Pedroso et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603
Pedroso et al., Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers.., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603
Aug 2021   Source   PDF  
  All Studies   Meta
Retrospective 45 healthcare workes in Brazil, showing lower creation of antibodies with multiple doses of ivermectin, which may be expected due to the antiviral activity as demonstrated in multiple studies. Authors appear unaware of these studies, citing only earlier in vitro research, which they misinterpret to suggest that therapeutic concentrations are not reached (for details on why this is incorrect see []). Authors combine no dose and one dose. Clinical outcomes and timing of treatment are not provided.
Pedroso et al., 12 Aug 2021, peer-reviewed, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: ARTICLE IN PRESS braz j infect dis. 2021;xxx(xx):101603 The Brazilian Journal of INFECTIOUS DISEASES w w w. e l s e v i e r. c o m / l o c a t e / b j i d Brief Communication Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response Q1 1X XCXD elia Pedroso D2XaX , D3X XSara Vaz aD4X X , D5X XEduardo Martins Netto aD6X X , D7X XDaniele Souza D8XaX , D9X XFelice Deminco aD10X X , D1X XRafaela Mayoral D12XaX , D13X XEliana Menezes aD14X X , D15X XAna Patricia Amancio da Cunha aD16X X , D17X XAndres Moreira-Soto D18XbX , D19X XIan Felix Drexler D20Xb,c X , a, D21X XCarlos Brites D2X X *  rio Professor Edgard Santos, Laboratorio de Pesquisa em Federal University of Bahia, Complexo Hospitalar Universita Infectologia (LAPI), Bahia, BA, Brazil b € tsmedizin Berlin, corporate member of Freie Universita € t Berlin, Humboldt-Universita € t zu Berlin, Charite-Universita a Institute of Virology, Berlin, Germany German Centre for Infection Research, Berlin, Germany c A R T I C L E I N F O A B S T R A C T Article history: Background: Over-the-counter use of ivermectin amongst other drugs as SARS-CoV-2 treat- Received 19 May 2021 ment has been increasingly common, despite the lack of evidence on its clinical efficacy. Accepted 5 July 2021 Objective: To evaluate the effect of ivermectin use on production of antibodies against SARS- Available online xxx CoV-2 in health care workers (HCW) diagnosed with COVID-19 and of Th1/Th2 cytokines by stimulated peripheral blood mononuclear cells of the same cohort (PBMCs). Methods: This cross-sectional study evaluated seroconversion and neutralizing antibodies  rio Professor Edgard Santos (Salvaproduction in HCW at Complexo Hospitalar Universita dor, Brazil), diagnosed with COVID-19 from May to July, 2020, as well as in vitro production of antibody against SARS-CoV-2 and Th1/Th2 cytokines. Analyses were performed between December 2020 and February 2021. Participants were stratified according to the use of ivermectin (≤ 1 dose vs. multiple doses) for treatment of COVID-19. Results: 45 HCW were included (62% women). Mean age was 39 years, and disease severity was similar across groups. Neutralizing antibodies were detected less frequently in multiple doses (70%) vs. ≤ 1 dose (97%) groups, p = 0.02). PBMCs of patients in multiple doses group also were less likely to produce antibodies against SARS-CoV-2 following in vitro stimulation with purified spike protein in comparison with patients in ≤ 1 dose group (p < 0.001). PBMCs production of Th1/Th2 cytokines levels was similar across groups. Abdominal pain (15% vs 46%, p = 0.04), diarrhea (21% vs. 55%, p = 0.05) and taste perversion (0% vs. 18%, p = 0.05) were more frequently reported by participants that used multiple doses of ivermectin. Conclusions: Although there was no evidence for differential disease severity upon ivermectin use for treatment of COVID-19 it was associated with more gastro-intestinal side-effects and impairment of anti-SARS-CoV2 antibodies production, in a dose dependent manner. * Corresponding author. E-mail address: (C. Brites). 1413-8670/Ó 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BYNC-ND license ( Please cite this article as: C. Pedroso..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop